Deeply invasive candidiasis.
The incidence of invasive candidiasis is on the rise because of increasing numbers of immunocompromised hosts and more invasive medical technology. Recovery of Candida spp from several body sites in a critically ill or immunocompromised patient should raise the question of disseminated disease. Although identification to the species level and antifungal susceptibility testing should guide therapy, at this time amphotericin B preparations are the usual initial therapy for severe life-threatening disease. Azole therapy has an expanding body of evidence that proves it is as effective as and safer than amphotericin B therapy. Some forms of candidiasis (e.g., those with ocular, bone, or heart involvement) require a combined medical and surgical approach.
Ostrosky-Zeichner
Luis
L
Division of Infectious Diseases, University of Texas-Houston Medical School, 6431 Fannin, JFB 1.728, Houston, TX 77030, USA. Luis.Ostrosky-Zeichner@uth.tmc.edu
Rex
John H
JH
Bennett
John
J
Kullberg
Bart-Jan
BJ
D019072:Antibiotic Prophylaxis; D000935:Antifungal Agents / Q000627:therapeutic use*; D001393:Azoles / Q000494:pharmacology / Q000627:therapeutic use; D002177:Candidiasis / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D002985:Clinical Protocols / Q000145:classification / Q000592:standards; D004696:Endocarditis / Q000382:microbiology; D015821:Eye Infections, Fungal / Q000453:epidemiology; D016469:Fungemia / Q000150:complications; D005658:Fungi / Q000472:pathogenicity; D005767:Gastrointestinal Diseases / Q000382:microbiology; D006801:Humans; D008172:Lung Diseases, Fungal / Q000382:microbiology; D010532:Peritoneal Diseases / Q000382:microbiology; D014552:Urinary Tract Infections / Q000382:microbiology
D000935:Antifungal Agents; D001393:Azoles